Kura Oncology, Inc. (KURA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 30M 60M 90M Q4 '25: 67.5M Q1 '26: 71.6M Q2 '26: 77.2M Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q4 '10: -20.5K Q1 '11: -20.8K Q2 '11: -21.6K Q3 '11: -22.7K Q4 '11: -23.4K Q1 '12: -23.4K Q2 '12: -22.6K Q3 '12: -21.9K Q4 '12: -22.3K Q1 '13: -22.8K Q2 '13: -23.3K Q3 '13: -23K Q4 '13: -22.7K Q1 '14: -22.2K Q2 '14: -21.9K Q3 '14: -22.2K Q4 '14: -23.9K Q4 '24: -193.2M Q1 '25: -203.4M Q2 '25: -219.7M Q3 '25: -239.8M Q4 '25: -303.6M Q1 '26: -317.7M Q2 '26: -318.1M Q2 '11 Q1 '12 Q4 '12 Q3 '13 Q2 '14 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-300M -150M 0 150M 300M 450M Q3 '16: -26.7M Q4 '16: -27.6M Q1 '17: -28.5M Q2 '17: -29.6M Q3 '17: -32M Q4 '17: -35.4M Q1 '18: -42.5M Q2 '18: -49.4M Q3 '18: -55.1M Q4 '18: -60.4M Q1 '19: -59.8M Q2 '19: -60M Q3 '19: -61.4M Q4 '19: -63.1M Q1 '20: -68.4M Q2 '20: -74M Q3 '20: -81.3M Q4 '20: -89.6M Q1 '21: -101.1M Q2 '21: -114.3M Q3 '21: -123.9M Q4 '21: -130.5M Q1 '22: -132.2M Q2 '22: -133.3M Q3 '22: -135.5M Q4 '22: -135.8M Q1 '23: -137.5M Q2 '23: -139.9M Q3 '23: -143M Q4 '23: -152.6M Q1 '24: -168.1M Q2 '24: -181.8M Q3 '24: -197.6M Q4 '24: -174M Q1 '25: -181.9M Q2 '25: -197.2M Q3 '25: -216.9M Q4 '25: -278.7M Q1 '26: -294.6M Q2 '26: -296.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '16: -24.2M Q4 '16: -25.3M Q1 '17: -26.7M Q2 '17: -26.9M Q3 '17: -27.7M Q4 '17: -28.4M Q1 '18: -32.7M Q2 '18: -39.2M Q3 '18: -45.9M Q4 '18: -48.7M Q1 '19: -50.1M Q2 '19: -51.9M Q3 '19: -51M Q4 '19: -54.8M Q1 '20: -60.3M Q2 '20: -60.6M Q3 '20: -65.5M Q4 '20: -69.8M Q1 '21: -78.5M Q2 '21: -91.9M Q3 '21: -99.5M Q4 '21: -104.6M Q1 '22: -108.2M Q2 '22: -110.5M Q3 '22: -106.9M Q4 '22: -110.1M Q1 '23: -113.8M Q2 '23: -109M Q3 '23: -117M Q4 '23: -124.8M Q1 '24: -137.8M Q2 '24: -154.7M Q3 '24: -169.1M Q4 '24: 134.3M Q1 '25: 111.2M Q2 '25: 125M Q3 '25: 87.8M Q4 '25: -64.1M Q1 '26: -78M Q2 '26: -111.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '15: -12.4M Q4 '15: -18M Q4 '20: -72M Q1 '21: -80.2M Q2 '21: -93.1M Q3 '21: -100.8M Q4 '21: -105.7M Q1 '22: -109.4M Q2 '22: -111.5M Q3 '22: -107.6M Q4 '22: -110.7M Q1 '23: -114.4M Q2 '23: -109.6M Q3 '23: -117.2M Q4 '23: -125M Q1 '24: -138M Q2 '24: -154.8M Q3 '24: -169.2M Q4 '24: 133.8M Q1 '25: 110.6M Q2 '25: 122.9M Q3 '25: 83.1M Q4 '25: -70.7M Q1 '26: -84.5M Q2 '26: -117.4M Q3 '15 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '21: 66.3M Q3 '21: 66.4M Q1 '22: 66.6M Q2 '22: 66.7M Q3 '22: 66.9M Q1 '23: 68.4M Q2 '23: 69.8M Q3 '23: 77.2M Q1 '24: 83.9M Q2 '24: 86.6M Q3 '24: 87M Q1 '25: 87.4M Q2 '25: 87.6M Q3 '25: 87.6M Q1 '26: 88.6M Q2 '26: 88.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '16: -1.39 Q4 '16: -1.47 Q1 '17: -1.50 Q2 '17: -1.54 Q3 '17: -1.55 Q4 '17: -1.53 Q1 '18: -1.60 Q2 '18: -1.65 Q3 '18: -1.67 Q4 '18: -1.73 Q1 '19: -1.64 Q2 '19: -1.57 Q3 '19: -1.53 Q4 '19: -1.50 Q1 '20: -1.55 Q2 '20: -1.57 Q3 '20: -1.63 Q4 '20: -1.69 Q1 '21: -1.73 Q2 '21: -1.84 Q3 '21: -1.92 Q4 '21: -1.97 Q1 '22: -2.00 Q2 '22: -2.01 Q3 '22: -2.04 Q4 '22: -2.03 Q1 '23: -2.04 Q2 '23: -2.05 Q3 '23: -2.02 Q4 '23: -2.08 Q1 '24: -2.17 Q2 '24: -2.23 Q3 '24: -2.36 Q4 '24: -2.03 Q1 '25: -2.10 Q2 '25: -2.26 Q3 '25: -2.48 Q4 '25: -3.18 Q1 '26: -3.35 Q2 '26: -3.37 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.